| scholarly article | Q13442814 |
| P50 | author | Josep M. Llovet | Q37393125 |
| P2093 | author name string | Josep M Llovet | |
| P2860 | cites work | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 |
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening | Q34701235 | ||
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | Q36984575 | ||
| Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
| Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. | Q38176242 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. | Q54526554 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 560-562 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma | |
| P478 | volume | 25 |
Search more.